Christopher Jonkergouw
CEO
Arivin Therapeutics
Arivin Therapeutics develops novel antimicrobial therapies that target bacterial virulence factors to combat antimicrobial resistance. Their dual-action approach neutralizes bacterial toxins and disrupts biofilms, aiming to provide sustained efficacy against resistant pathogens by minimizing selective pressure.
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
The escalating crisis of antimicrobial resistance (AMR) is characterized by pathogens evolving resistance mechanisms faster than new treatments can be developed, leading to increased mortality and healthcare burdens. Current antibiotic development timelines are unsustainable, with resistance emerging rapidly after market introduction.
Solution
Arivin Therapeutics is developing novel antimicrobial therapies designed to circumvent traditional resistance pathways by targeting bacterial virulence factors. Their lead programs focus on neutralizing bacterial toxins and disrupting biofilms, which are critical for pathogen survival and infection establishment. This dual-action approach aims to maintain therapeutic efficacy over extended periods, addressing the limitations of conventional bactericidal or bacteriostatic agents. By neutralizing virulence rather than directly killing bacteria, the therapies are engineered to minimize the selective pressure that drives rapid resistance development. This strategy is intended to provide "Future-Proof" treatments capable of sustained effectiveness against a broad spectrum of current and emerging resistant pathogens.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions focused on infectious disease and antimicrobial drug development.
Features
- Dual-acting therapeutic agents targeting bacterial toxins and biofilms simultaneously.
- Mode of action focuses on virulence factor neutralization, distinct from bactericidal or bacteriostatic mechanisms.
- Designed to minimize the selective pressure that drives rapid antimicrobial resistance development.
- Lead programs demonstrate efficacy against highly resistant bacterial strains.
- Published research in Nature Communications detailing the dual-acting anti-virulence strategy.
- Platform technology focused on disrupting bacterial virulence factors.